ClinicalTrials.gg
Status unknownNCT03757936Updated May 23, 2019

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HLX04 and HLX10 in Solid Tumor, sponsored by Shanghai Henlius Biotech. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-23.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, male or female
  2. Patient with or cytologically confirmed advanced malignant solid tumors who have failed standard of care, or has no standard-of-care therapy or are not suitable for standard of care at the present stage;
  3. (ECOG) performance status 0 to 1;
  4. greater than 3 months;
  5. Patient must have at least one measurable tumor lesion as defined by v1.1; the lesion concerned must not be a bone if only one target lesion is present;
  6. Has adequate organ functions;
  7. If the subject is a patient with hepatocellular carcinoma, classification must be A.
  8. A qualified patient (male or female) of must agree to use reliable methods (hormonal, or barrier method or abstinence) for the course of the study and through at least 6 months after the last dose; a female patient of childbearing potential must have negative blood pregnancy test within 7 days prior to enrollment;
  9. The subject must give his/her to this study prior to the trial, and voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Histopathological confirmed head and neck cancer or squamous-cell lung cancer, or bleeding tendency in the tumor lesion judged by the investigator;
  2. Has received antitumor therapy like radiotherapy, chemotherapy, targeted therapy, endocrinal therapy or immunotherapy, or other clinical study drug therapy within 4 months prior to the initial drug administration;
  3. Has received a surgical operation on major viscera or experienced apparent trauma within 4 weeks from the initial drug administration, or experienced subcutaneous venous access device implantation within 7 days;
  4. The adverse reactions which occurred in the previous antitumor treatment were not recovered to ≤ grade 1 based on 4.03 assessment (except for hair loss);
  5. Evidences of lesion in the patient's central nervous system;
  6. Previously experienced ≥ grade 3 immune-related adverse event during immunotherapy;
  7. Active, or history of disease which may relapse (for example, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.);
  8. Currently having or have had interstitial lung disease;
  9. Uncontrollable active infection(s);
  10. History of immunodeficiency, including antibody positive;
  11. Known active ; or virus infections;
  12. Has bleeding tendency;
  13. History of severe cardiovascular diseases;
  14. Known gastrointestinal diseases as follows:

    Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the ; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or > moderate esophageal varices;

  15. Known to Bevacizumab, or other , anti-PD-L1 monoclonal antibody agents;
  16. Pregnant or breastfeeding female.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HLX04+HLX10

    HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.

    Drug: HLX04 · Drug: HLX10

Interventions

  • DrugHLX04

    Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection

  • DrugHLX10

    Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of HLX04 plus HLX10 in patients with advanced solid tumors

    The MTD is the dose with toxicity rate (estimated by isotonic regression) most approximate to the target one (30%).

    Time frame: 28 days

  2. Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors

    DLT is defined as the occurrence of the following adverse events (unless judged by the investigator to be definitely unrelated to HLX04 or HLX10) within Cycle 1 (i.e., from Cycle 1 Day 1 to Cycle 1 Day 28)

    Time frame: 28 days

Secondary outcomes

  1. PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors

    Peak Plasma Concentration (Cmax) for single dose and multiple doses

    Time frame: Day 1 of treatment up to 2 years

  2. PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors

    Area under the plasma concentration versus time curve (AUC) for single dose and multiple doses

    Time frame: Day 1 of treatment up to 2 years

  3. Objective Response Rate (ORR) of HLX04 plus HLX10 in patients with advanced solid tumors

    ORR determined by RECIST criteria

    Time frame: Day 1 of treatment up to 2 years

  4. Disease Control Rate (DCR) of HLX04 plus HLX10 in patients with advanced solid tumors

    DCR determined by RECIST criteria

    Time frame: Day 1 of treatment up to 2 years

  5. Duration of Response (DOR) of HLX04 plus HLX10 in patients with advanced solid tumors

    DOR determined by RECIST criteria

    Time frame: Day 1 of treatment up to 2 years

  6. Progression-Free Survival (PFS) of HLX04 plus HLX10 in patients with advanced solid tumors

    PFS determined by RECIST criteria

    Time frame: Day 1 of treatment up to 2 years

  7. Overall Survival (OS) of HLX04 plus HLX10 in patients with advanced solid tumors

    OS determined by RECIST criteria

    Time frame: Day 1 of treatment up to 2 years

  8. Immunogenicity

    Anti-drug Antibody (ADA) Testing

    Time frame: Day 1 of treatment up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Shanghai East Hospital
    Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for Sep 2019, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2018
First posted
Nov 29, 2018
StartActual
Nov 27, 2018
Primary completionEst.
Sep 27, 2019
CompletionEst.
Dec 27, 2020
Last update
May 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03757936
Responsible party
Sponsor
First posted
Nov 29, 2018
Start date
Nov 27, 2018
Primary completion
Sep 27, 2019 (estimated)
Completion
Dec 27, 2020 (estimated)
Last update
May 23, 2019

Study contacts

Joanne Wang
Contact
Joanne_wang@henlius.com
+86-021-33395800-6024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HLX04 · Serplulimab

Start the discussion